Methods to potentiate intravenous estramustine phosphate

Details Methods to potentiate intravenous estramustine phosphate Methods to potentiate intravenous estramustine phosphate

2005-02-01

2005-02-01

Badio, Barbara P. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

06849616

ABSTRACT:
Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administered at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.

REFERENCES:
patent: 4584136 (1986-04-01), Yoshida et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5424073 (1995-06-01), Rahman et al.
patent: 5616341 (1997-04-01), Mayer et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5780446 (1998-07-01), Ramu
patent: 5795882 (1998-08-01), Bishop et al.
A. Yagoda et al,Journal of Urology, vol. 145, p. 384A, Abstract 686 (1991).
S. B. Andersson, et al,Acta Pharm Suecica, vol. 19, pp. 1-10 (1962).
S. Batra, et al,Int. J. Cancer, vol. 68, pp. 644-649 (1996).
A.T. Bergenheim, et al,Br. J. Cancer, vol. 67, pp. 358-361 (1993).
J. Bergh, et al,Cancer Res., vol. 48, pp. 4615-4619 (1988).
P. Björk, et al,Anticancer Res., vol. 11(3), pp. 1173-1182 (1991).
P. Björk, et al,Pancreas, vol. 6, No. 1, pp. 1:77-89 (1991).
B. Dahllöf, et al,Cancer Res., vol. 53, pp. 4573-4581 (1993).
M. Edgren, et al,Acta Oncologica, vol. 35(4), pp. 483-488 (1996).
S. Eklöv, et al,The Prostate, vol. 20, pp. 43-50 (1992).
S. Eklöv, et al,Anticancer Res., vol. 16(4A), pp. 1819-1822 (1996).
S. Flütchter, et al,The Prostate, vol. 14, pp. 27-43 (1989).
B. Forsgren, et al,Proc. Natl. Acad. Sci., USA, vol. 76, pp. 3149-3153 (1979).
P. O. Gunnarson, et al,Eur. J. Clin. Pharmacol., vol. 26, pp. 113-119 (1984).
P. O. Gunnarsson, et al,Scand. J. Urol. Nephrol., vol. 15, pp. 201-206 (1981).
B. Hartley-Asp,The Prostate, vol. 5, pp. 93-100 (1984).
B. Hartley-Asp, et al.J. Urology, vol. 127, pp. 818-822 (1982).
G. Hudes, et al,Seminars Oncology, vol. 22, No. 3, Suppl. 6, pp. 6-11 (1995).
G. R. Hudes, et al,J. Clin. Oncology, vol. 10, No. 11, pp. 1754-1761 (1992).
S. Keren-Rosenberg, et al,Seminars in Oncology, vol. 24, No. 1, Suppl. 3, pp. S3-26 to S3-29 (1997).
B. Lindberg,Journal of Urology, vol. 108, pp. 303-305 (1972).
U. Maier, et al,Eur. Urol., vol. 17, 216-218 (1990).
M. M. Mareel, et al,Cancer Res., vol. 48, pp. 1842-1849 (1988).
G. P. Murphy et al,Seminars in Oncology, vol. 10, No. 3, Suppl 3, pp. 34-42 (1983).
R. Nagel, et al,British Journal of Urology, vol. 49, pp. 73-79 (1977).
B. J. Norlén, et al,Journal of Urology, vol. 140, pp. 1058-1062 (1988).
D. P. Petrylak,Cancer Investigation, vol. 16, Supp 1, p. 62-63 (1997).
K. J. Pienta, et al,Journal of Urology, vol. 149, pp. 1622-1625 (1993).
K. J. Pienta, et al,J. Clinical Oncology, vol. 12, No. 10, pp. 2005-2012 (1994).
A. D. Seidman, et al,J. Urology, vol. 147, pp. 931-934 (1992).
L. A. Speicher,Cancer Res., vol. 52, pp. 4433-4440 (1992).
M. E. Stearns, et al,J. Cell Science, vol. 89, pp. 331-342 (1988).
E. von Schoultz, et al,Melanoma Res., vol. 4(6), pp. 401-405 (1994).
P. H. Walz, et al,Akt. Urol., vol. 27, pp. 92-93 (1996).
G Hudes et al,Journal of Clinical Oncology, vol. 20, No. 4, pp. 1115-1127 (2002).
E Hovey et al,American Society of Clinical Oncology, #2424 (Abstract only) (2001).
S Talbot et al,American Society of Clinical Oncology, #437 (Abstract only) (2000).
M. R. Smith et al.,American Society of Clinical Oncology, #137 (Abstract only) (1999).
P Kim et al,American Society of Clinical Oncology, #509 (Abstract only) (1999).
D Panda et al,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 10560-10564 (1997).
U. Maier et al,Eur Urol, vol. 17, pp. 216-218 (1990).
B. Hartley-Asp et al,Proc. Am. Soc. Clin. Onc., vol. 20, p. 183a (2001).
Examination Report issued in Israel Patent Application No. 133,612 on Nov. 10, 2002, with attached English translation of the Substantive Portion, (English translation only).
Keren-Rosenberg et al,Semin. Oncol., vol. 24 (1), Suppl. 3, pp. S3/26-S3/29 (1997), Database Chemical Abstracts on STN, Abstract No. 126:271944, (Abstract only).
Keren-Rosenberg et al,Proc. Am. Soc. Clin. Oncol.vol. 15, p. 181 (1996),Database Drugu on STN, Abstract No. 96-40815, (Abstract only).
Hudes et al,Semin. Oncol., vol. 22 (5), Suppl. 12, pp. 41-45 (1995), Database Chemical Abstracts on STN, Abstract No. 124:105826, (Abstract only).
Pitenta,J. Urol., vol. 149, No. 4, Suppl. 428 A (1993), Database Drugu on STN, Abstract No. 93-26752, (Abstract only).
Hudes, et al., “Paclitaxel Plus Estramustine in Metastatic Homrone-Refractory Prostate Cancer”, Seminars in Oncology, vol. 22, No. 5, suppl. 12, pp. 41-45 (1995).
Garcia, et al., “Phase I and Pharmacologic Study of Estramustine Phsophate and Short Infusions of Paclitaxel in Women with Solid Tumors”, Journal of Clinical Oncology, vol. 16, No. 9, pp. 2959-2963 (1998).

Affiliated with

Also associated with

Rating

Methods to potentiate intravenous estramustine phosphate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to potentiate intravenous estramustine phosphate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to potentiate intravenous estramustine phosphate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3492859